[{"address1": "28-8, Honkomagome 2-chome", "address2": "Bunkyo-ku", "city": "Tokyo", "zip": "113-8650", "country": "Japan", "phone": "81 3 5977 5007", "fax": "81 3 5977 5131", "website": "https://www.kaken.co.jp", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; Seladelpar that is in phase I clinical trial for primary biliary cholangitis; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.", "fullTimeEmployees": 1135, "companyOfficers": [{"maxAge": 1, "name": "Mr. Hiroyuki  Horiuchi", "title": "President & Representative Director", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tomoyuki  Koseki", "title": "Chief Officer of Marketing & Sales Division", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Naoyuki  Ishida", "title": "GM of Human Resources Department & Corporate Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Satoshi  Murakami", "title": "Chief Officer of Regulatory Affairs Division", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Masanao  Shimano Ph.D.", "title": "Chief Officer of Production Division, Chief of Shizuoka Factory & Corporate Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Hironobu  Ogura", "title": "Chief of Drug Research Centers", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Masashi  Suzudo", "age": 61, "title": "GM of Corporate Planning & Coordination Department and Director", "yearBorn": 1962, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Hirofumi  Fujii", "title": "Corporate Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mitsuru  Watanuki", "title": "Chief Officer of R&D Division and Corporate Officer", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 8, "compensationRisk": 6, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1725148800, "maxAge": 86400, "priceHint": 2, "open": 22.3, "dayLow": 22.3, "dayHigh": 22.3, "regularMarketOpen": 22.3, "regularMarketDayLow": 22.3, "regularMarketDayHigh": 22.3, "dividendRate": 0.96, "dividendYield": 0.0345, "exDividendDate": 1727395200, "payoutRatio": 0.78129995, "beta": 0.279, "trailingPE": 21.312979, "volume": 202, "regularMarketVolume": 202, "averageVolume": 15, "bid": 25.62, "ask": 29.28, "marketCap": 1062065664, "fiftyTwoWeekLow": 22.3, "fiftyTwoWeekHigh": 29.27, "priceToSalesTrailing12Months": 0.014720653, "fiftyDayAverage": 24.97474, "twoHundredDayAverage": 24.95216, "trailingAnnualDividendRate": 150.0, "trailingAnnualDividendYield": "Infinity", "currency": "USD", "enterpriseValue": -61653676032, "profitMargins": 0.10075, "floatShares": 28871880, "sharesOutstanding": 37869700, "heldPercentInsiders": 0.1933, "heldPercentInstitutions": 0.25816, "bookValue": 3763.402, "priceToBook": 0.0074188192, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": -0.301, "netIncomeToCommon": 7269000192, "trailingEps": 1.31, "lastSplitFactor": "1:2", "lastSplitDate": 1443398400, "enterpriseToRevenue": -0.855, "enterpriseToEbitda": -5.238, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "KKPCF", "underlyingSymbol": "KKPCF", "shortName": "KAKEN PHARMACEUTICAL", "longName": "Kaken Pharmaceutical Co., Ltd.", "firstTradeDateEpochUtc": 1607524200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fd57e345-f2ce-3dd1-a61d-cae5b7cf18d7", "gmtOffSetMilliseconds": -14400000, "currentPrice": 27.92, "recommendationKey": "none", "totalCash": 66560999424, "totalCashPerShare": 1757.631, "ebitda": 11770250240, "totalDebt": 3849999872, "quickRatio": 3.944, "currentRatio": 4.722, "totalRevenue": 72148000768, "debtToEquity": 2.701, "revenuePerShare": 1906.839, "returnOnAssets": 0.0328, "returnOnEquity": 0.051859997, "earningsGrowth": -0.309, "revenueGrowth": 0.006, "grossMargins": 0.53411, "ebitdaMargins": 0.16314, "operatingMargins": 0.15071, "financialCurrency": "JPY", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]